Stevanato Group S.p.A.

Scaled global drug-containment/delivery leader compounding revenue ~21% with strong margins and top-tier cash generation.

Strengths

• Top-decile operating margin (16.8%, 89th pct), OCF margin (24%, 92.8th pct) and interest coverage (100th pct)
• Revenue +21% (70.5th pct) and net income +34% (74th pct); partner to 23 of top 25 pharma (durable franchise)
• Strong ROIC 8.1% (76th pct) and ROA (83.6th pct)

Risks

• Gross margin weak for sector (29%, 12.7th pct), reflecting capacity ramp and capital intensity
• Modest ROE (9.4%) and thin FCF margin (1.9%) amid heavy greenfield capex
• China/geopolitical and customer-destocking exposure

Notable findings

• Strong balance sheetStrong balance sheet — $153M cash & investments
• Insider sellingInsider selling — 4 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, last 6mo) Form 4 ↗